Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 307Lung Neoplasms 111Adenocarcinoma of Lung 23Non-Squamous Non-Small Cell Lung Cancer 21Neoplasms 21Adenocarcinoma, Bronchiolo-Alveolar 15Brain Neoplasms 14Neoplasm Metastasis 10Squamous Cell Carcinoma of Head and Neck 5Respiratory Tract Diseases 5Carcinoma 5Breast Neoplasms 5Adenocarcinoma 5Thoracic Neoplasms 4Recurrence 4Pancreatic Neoplasms 4NSCLC 4Colorectal Neoplasms 4Colonic Neoplasms 4Salivary Gland Neoplasms 3Respiratory Tract Neoplasms 3Rectal Neoplasms 3Lung Diseases 3Esthesioneuroblastoma, Olfactory 3Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3Thymoma 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pleural Effusion, Malignant 2

Interventions

zenocutuzumab 1seribantumab 1pembrolizumab 1osimertinib 1enzalutamide 1cemiplimab 1Vascular Endothelial Growth Factor A 1Paroxetine 1Paclitaxel 1Itraconazole 1Erlotinib Hydrochloride 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × Erlotinib Hydrochloride × Thoracic × Clear all
NCT00994123 2016-08-22

A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Merrimack Pharmaceuticals

Phase 1/2 Completed
162 enrolled 11 charts
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡